Risk of transmission of HBV. Closely monitor hepatobiliary & renal parameters in patients w/ decompensated liver disease & Child Pugh Turcotte score >9, cirrhosis. Monitor hepatic function at repeated intervals w/ follow-up for at least 6 mth after discontinuation of treatment. Advanced liver disease or cirrhosis. Patients w/ renal impairment (CrCl <15 mL/min) not receiving haemodialysis, co-infected w/ hepatitis C or D virus. Potential risk of nephrotoxicity. HIV Ab testing should be offered to all HBV-infected patients whose HIV-1 infection status is unknown before initiation of therapy. Concomitant use w/ products containing tenofovir alafenamide, tenofovir disoproxil fumarate or adefovir dipivoxil; certain anticonvulsants (eg, carbamazepine, oxcarbazepine, phenobarb & phenytoin), antimycobacterials (eg, rifampicin, rifabutin & rifapentine) or St. John's wort; strong P-gp inhibitors (eg, itraconazole & ketoconazole). Galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. Pregnancy & lactation.
J05AF13 - tenofovir alafenamide ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
